Aytu BioPharma, Inc. — Form 10-K Summary
Period: Fiscal year ended June 30, 2022; comparative period is fiscal 2021. The request metadata says “2021 Q4,” but the filing covers the full fiscal year ended June 30, 2022.
Business context
Aytu is a commercial-stage pharmaceutical and consumer-health company. Its BioPharma segment sells prescription products, including ADHD medicines and pediatric products; its Consumer Health segment sells OTC and wellness products. Its principal development programs are AR101 (enzastaurin) for vascular Ehlers-Danlos syndrome (VEDS) and Healight, an investigational UV-A endotracheal catheter for respiratory infections.
Financial results and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Net revenue | $96.7 million | $65.6 million |
| Gross profit | $52.3 million | $29.2 million |
| Gross margin | 54% | 44% |
| Operating loss | $111.6 million | $58.9 million |
| Net loss | $110.2 million | $58.3 million |
| Cash used in operating activities | $28.8 million | $26.0 million |
- Revenue grew 47%, mainly reflecting a full-year contribution from the ADHD portfolio acquired with Neos in March 2021. ADHD revenue was $42.9 million, pediatric revenue $16.1 million, Consumer Health revenue $35.5 million, and other revenue $2.2 million.
- Gross margin improved primarily from higher volume and cost reductions in ADHD and pediatric products, and an inventory impairment in the prior year. Consumer Health margins were pressured by growth in lower-margin e-commerce sales.
- Operating expenses included $75.5 million of impairment charges, including $65.8 million of goodwill impairment. The company reported no goodwill at June 30, 2022; year-end intangible assets were $70.6 million.
- Cash and cash equivalents were $19.4 million at June 30, 2022, down from $49.6 million a year earlier. Current assets were $59.9 million and current liabilities $64.4 million. The filing identifies substantial doubt about the company’s ability to continue as a going concern, citing cash needs and continued operating losses.
- At year-end, $3.8 million was outstanding under the Eclipse revolving facility and $15.0 million principal under the Avenue Capital term loan; the balance-sheet carrying value of debt, including finance leases and net of discounts, was $14.4 million. The Avenue loan matures January 2025 and bears interest at the greater of prime or 3.25%, plus 7.4%. The amended Eclipse facility matures January 2025 and bears interest at SOFR plus 4.50%. Both facilities are secured and include restrictive covenants.
- Cash used in investing activities was $3.2 million; cash provided by financing activities was $1.5 million. Financing cash flows included $15.0 million of new debt and $11.7 million net stock proceeds, offset by debt repayments, reduced revolving borrowings, and other payments.
Material changes, outlook, and risks
- Compared with FY2021, revenue and gross profit increased, but net loss widened substantially, largely because impairment expense rose from $12.8 million to $75.5 million. R&D expense increased to $14.4 million from $5.6 million, primarily for AR101 trial preparation and milestone payments.
- The company discontinued or planned to divest five non-core products. Those products generated $2.2 million of FY2022 revenue and a $0.7 million gross loss. A May 2022 settlement with Tris reduced future minimum-payment obligations by approximately $8 million; the filing states settlement payments of approximately $6 million to $9 million are due in installments from December 2022 through July 2024.
- AR101 received U.S. and European orphan-drug designations and U.S. Fast Track designation; the FDA cleared its IND. The company expected enrollment in the approximately 260-patient PREVEnt trial to begin by early 2023. These designations do not assure approval or commercial success.
- Healight’s preclinical porcine study reported a 46% reduction in multidrug-resistant Pseudomonas aeruginosa versus controls after two treatments. A larger study was underway, with results expected by late 2022 or early 2023. The company said further significant development would likely require a partner and was considering licensing or divestiture.
- Management expected to transfer ADHD manufacturing to a contract manufacturer, targeting production in mid-to-late 2023, subject to technology transfer, bioequivalence work, regulatory filings, and approval.
- After year-end, an August 2022 stock offering generated $10.0 million gross and $9.1 million net proceeds. The pre-funded warrants were exercised; the offering also included warrants to purchase 23.3 million shares, creating potential dilution. Management planned to use proceeds for pipeline development, commercial growth, and general corporate purposes.
- Key risks include going-concern financing needs, ongoing losses, debt covenants and repayment obligations, potential equity dilution, dependence on a small number of customers (three accounted for 78% of FY2022 gross revenue and 94% of year-end gross receivables), product and supplier concentration, clinical and regulatory uncertainty, and competition. COVID-19 and inflation-related supply-chain pressures were also cited.
- Nasdaq notified the company in May 2022 that its share price had remained below the $1.00 minimum bid requirement. The company had a compliance period and was considering a reverse stock split, subject to shareholder approval. The filing also describes opioid-related county litigation, shareholder suits concerning equity awards, and a derivative suit; outcomes and financial effects were not clear.
- No quantified financial guidance was provided. The filing’s development and manufacturing milestones are expectations, not assurances. Management reported effective disclosure controls and internal control over financial reporting at June 30, 2022; the auditor’s report nevertheless highlighted goodwill and intangible-asset valuation as a critical audit matter.
Important facts for investors to verify
- Review the going-concern disclosures, cash runway assumptions, post-year-end financing, and any subsequent financing or asset-sale developments.
- Check the complete debt agreements and current covenant compliance, borrowing availability, interest costs, maturity terms, and scheduled Tris and other contractual payments.
- Assess the assumptions behind the $75.5 million impairment charges and remaining intangible-asset values, including forecasts and discount rates.
- Track actual product-level sales, gross margins, customer concentration, and the effect of discontinued products and generic-entry timelines.
- Confirm PREVEnt trial startup and enrollment, Healight study results and partner status, and the timing and regulatory progress of the ADHD manufacturing transfer.
- Evaluate potential dilution from outstanding warrants, future equity needs, and the status of Nasdaq minimum-bid compliance.